different.

Serial No. 09/171,697 - - - - 3

of oxygen, nitrogen, sulphur and phosphorus; wherein R^a represents hydrogen or hydrocarbon as described above;]

wherein each of the R² and R³ substituents can be the same or different; and X represents halogen and each of the 5, 7, substituents can be the same or

Cancel claim 20.

Rewrite claim 21 to read:

21(Amended). A method [suitable] for treating a patient to prevent or ameliorate neuroexcitability disorders comprising administering to a patient in need of such treatment an effective amount of an antagonist compound of claim 12 exhibiting affinity for both the strychnine-insensitive glycine binding site on N-methyl-D-aspartate receptor and voltage dependent sodium channels.

Rewrite claim 22 to read:

22(Amended). The method of claim 21 wherein the <u>compound</u> [compounds] is selected from the group consisting of <u>N,N-diphenyl-substituted-4-ureido-5,7-dichloro-2-carboxy-quinoline</u> [N-substituted-4-ureido-5,7-dihydro-2-carboxy quinoline], a tautomer thereof, a pharmacologically acceptable ester, amide, salt, ether and addition salt thereof.

Claim 23, line 1, delete "claim 20" and substitute therefor - claim 21 -

REMARKS

The courtesies extended to the applicants' representative during the interview with Mr. John Kight III, the Supervising Primary Examiner, are appreciated and gratefully acknowledged. Reconsideration of this application in light of the discussions had during the interview and the present amendments to the claims is requested.

Claims 11-19 and 21-23 are in the application. Claims 1-10 and 20 are canceled without prejudice in order to expedite the further prosecution of this application.

Claim 11 is amended so as to make this claim dependent on claim 12.

Claim 12 is amended to restrict the scope thereof to a preferred embodiment of the present invention and to obviate inadvertent editorial errors. Support for the present

Serial No. 09/171,697 - - - - 4

amendment to this claim is found in the specification, inter alia, on page 12 at lines 24-25 and line 30, on page 13 at lines 1-2, as well as in the Examples.

Claim 21 is amended to further define a method aspect of the present invention. This amendment is supported in the specification, inter alia, at page 15, line 22.

Claim 22 is amended to obviate inadvertent editorial errors. Amendments to this claim are supported in the specification on page 9 at lines 15-21.

Claim 23 is amended to obviate an inadvertent typographical error in reciting claim dependency. This amendment is supported in the specification on page 9 at lines 18-23.

The foregoing amendments to the claims are believed to dispose of all issues in this case and to place this application in condition for allowance. Early such action is solicited.

Respectfully submitted,

Talivaldis Ceputitis (Reg. No./20.818)

OLSON & HIERL, LTD. 20 North Wacker Drive 36th Floor Chicago, Illinois 60606 (312) 580-1180

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this RESPONSE AND AMENDMENT UNDER RULE 111 is being transmitted by facsimile transmission (Fax. No. 703-308-7922) on November 5, 1999.

Talivaldis Cepuritis (Reg. No. 20,818)